Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01510405 · ClinicalTrials.gov registry record
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- 42
- Enrollment target
NCT01510405 is a clinical trial that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 42 participants.
The verdict
NCT01510405 has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The investigators have characterized in preclinical Non-Small Cell Lung Cancer (NSCLC) models the proteomic expression profile associated with exposure to Aurora and Polo-like kinase inhibitors. The identification of proteomic expression patterns in patients with NSCLC would be an important step in defining the possible role of these agents as potential targeted therapies for this clinically important disease. This study proposes to evaluate resected non-small cell lung cancer specimens for these proteomic expression profiles.
Interventions
- OTHER Tissue Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-07 |
| Est. Completion | 2020-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01510405
The ClinicalTrials.gov registry entry for NCT01510405 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tissue Collection is the first listed.
NCT01510405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01510405 about?
NCT01510405 is a clinical study titled "Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer". The investigators have characterized in preclinical Non-Small Cell Lung Cancer (NSCLC) models the proteomic expression profile associated with exposure to Aurora and Polo-like kinase inhibitors. The identification of proteomic expression patterns in patients with NSCLC would be an important step in ...
What is the current status of trial NCT01510405?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2010-07. Estimated completion is 2020-04.
What interventions are being tested in trial NCT01510405?
The interventions under investigation include: Tissue Collection (OTHER).
Who is sponsoring clinical trial NCT01510405?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.